Ionis Pharmaceuticals, Inc. Announces 2024 Annual Meeting of Stockholders

Ticker: IONS · Form: DEF 14A · Filed: Apr 25, 2024 · CIK: 874015

Sentiment: neutral

Topics: Ionis Pharmaceuticals, Annual Meeting, Proxy Statement, Virtual Meeting, Stockholder Voting

TL;DR

<b>Ionis Pharmaceuticals, Inc. is holding its 2024 Annual Meeting of Stockholders virtually on June 6, 2024, and encourages early voting.</b>

AI Summary

IONIS PHARMACEUTICALS INC (IONS) filed a Proxy Statement (DEF 14A) with the SEC on April 25, 2024. Ionis Pharmaceuticals, Inc. will hold its 2024 Annual Meeting of Stockholders on June 6, 2024. The meeting will be conducted exclusively in a virtual format via live webcast. Stockholders can attend and participate online at www.virtualshareholdermeeting.com/IONS2024. Proxy materials are being furnished to stockholders over the Internet to reduce costs and environmental impact. The company encourages stockholders to vote their shares prior to the meeting.

Why It Matters

For investors and stakeholders tracking IONIS PHARMACEUTICALS INC, this filing contains several important signals. The virtual format allows for broader participation and reduces logistical costs associated with in-person meetings. The move to internet-based distribution of proxy materials aims to be more cost-effective and environmentally friendly.

Risk Assessment

Risk Level: — IONIS PHARMACEUTICALS INC shows moderate risk based on this filing. This filing is a routine proxy statement for an annual shareholder meeting and does not contain new financial or operational disclosures that would indicate significant risk.

Analyst Insight

Review the proxy statement for details on voting matters, executive compensation, and company performance before the June 6, 2024, annual meeting.

Key Numbers

Key Players & Entities

FAQ

When did IONIS PHARMACEUTICALS INC file this DEF 14A?

IONIS PHARMACEUTICALS INC filed this Proxy Statement (DEF 14A) with the SEC on April 25, 2024.

What is a DEF 14A filing?

A DEF 14A is a definitive proxy statement sent to shareholders before annual meetings, covering executive compensation, board nominations, and shareholder votes. This particular DEF 14A was filed by IONIS PHARMACEUTICALS INC (IONS).

Where can I read the original DEF 14A filing from IONIS PHARMACEUTICALS INC?

You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by IONIS PHARMACEUTICALS INC.

What are the key takeaways from IONIS PHARMACEUTICALS INC's DEF 14A?

IONIS PHARMACEUTICALS INC filed this DEF 14A on April 25, 2024. Key takeaways: Ionis Pharmaceuticals, Inc. will hold its 2024 Annual Meeting of Stockholders on June 6, 2024.. The meeting will be conducted exclusively in a virtual format via live webcast.. Stockholders can attend and participate online at www.virtualshareholdermeeting.com/IONS2024..

Is IONIS PHARMACEUTICALS INC a risky investment based on this filing?

Based on this DEF 14A, IONIS PHARMACEUTICALS INC presents a moderate-risk profile. This filing is a routine proxy statement for an annual shareholder meeting and does not contain new financial or operational disclosures that would indicate significant risk.

What should investors do after reading IONIS PHARMACEUTICALS INC's DEF 14A?

Review the proxy statement for details on voting matters, executive compensation, and company performance before the June 6, 2024, annual meeting. The overall sentiment from this filing is neutral.

How does IONIS PHARMACEUTICALS INC compare to its industry peers?

Ionis Pharmaceuticals operates in the biopharmaceutical industry, focusing on the discovery, development, and commercialization of RNA-targeted therapeutics.

Are there regulatory concerns for IONIS PHARMACEUTICALS INC?

The filing is made under the Securities Exchange Act of 1934, specifically Section 14(a), which governs the solicitation of proxies.

Industry Context

Ionis Pharmaceuticals operates in the biopharmaceutical industry, focusing on the discovery, development, and commercialization of RNA-targeted therapeutics.

Regulatory Implications

The filing is made under the Securities Exchange Act of 1934, specifically Section 14(a), which governs the solicitation of proxies.

What Investors Should Do

  1. Review the proxy statement for agenda items and voting proposals.
  2. Register and attend the virtual annual meeting on June 6, 2024.
  3. Cast your vote prior to the meeting to ensure your shares are represented.

Key Dates

Year-Over-Year Comparison

This is a DEF 14A filing, which is a routine annual proxy statement and does not represent a change from previous filings in terms of its nature.

Filing Stats: 4,879 words · 20 min read · ~16 pages · Grade level 12 · Accepted 2024-04-25 16:50:45

Filing Documents

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 40 Securities Authorized for Issuance Under Equity Compensation Plans 42

EXECUTIVE COMPENSATION

EXECUTIVE COMPENSATION 43 Compensation Discussion and Analysis 43 Business Overview and Recent Achievements 44 Compensation of Executive Officers 69 Summary Compensation Table 70 Grants of Plan-Based Awards 71 Narrative to Summary Compensation Table and Grants of Plan-Based Awards Table 71 Pay Versus Performance 72 Outstanding Equity Awards at Fiscal Year-End – Executive Officers 77 Option Exercises and Stock Vested – Executive Officers 80 Post-Employment Compensation 80 Potential Payments Upon Termination or Change-of-Control 80 Director Compensation 82 Outstanding Equity Awards at Fiscal Year-End – Directors 84 Option Exercises and Stock Vested Directors 86 Certain Relationships and Related Transactions 86 CEO Pay Ratio 88 COMPENSATION COMMITTEE REPORT 89 AUDIT COMMITTEE REPORT 90 HOUSEHOLDING OF PROXY MATERIALS 91 Other Matters 91 Special Note Regarding Forward-Looking Statements 92 Appendix A A-1 Appendix B B-1 TABLE OF CONTENTS IONIS PHARMACEUTICALS, INC. 2855 Gazelle Court Carlsbad, CA 92010 PROXY STATEMENT FOR THE 2024 ANNUAL MEETING OF STOCKHOLDERS To Be Held on June 6, 2024 QUESTIONS AND ANSWERS ABOUT THESE PROXY MATERIALS AND VOTING Why did I receive a Notice Regarding the Availability of Proxy Materials on the Internet? The Board of Directors (the " Board ") of Ionis Pharmaceuticals, Inc. (the " Company ") is soliciting your proxy to vote at the 2024 Annual Meeting of Stockholders, including at any adjournments or postponements of the meeting. We are distributing our Notice of Annual Meeting and Proxy Materials (the " Notice ") by mail using the Notice and Access procedures established by the United States Securities and Exchange Commission (the " SEC "). The Notice is important because it contains a control number and instructions that will allow you to access our proxy materials and vote electronically through the Internet or to request printed proxy materials so you may v

View Full Filing

View this DEF 14A filing on SEC EDGAR

View on Read The Filing